ArticlePharmaceutics2022
Therapeutic Options for Recurrent Glioblastoma-Efficacy of Talaporfin Sodium Mediated Photodynamic Therapy.
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Emerging minimally invasive laser and light-based therapies for glioblastoma: a systematic review.Frontiers in oncology · 2025Pooled it
- Biophotonics point-of-care diagnostics in low-resource settings: a South African perspective.Journal of biomedical optics · 2026Review
- Photodynamic therapy using talaporfin sodium for grade 2/3 meningiomas: a preliminary study of safety, feasibility, and clinical outcomes.Journal of neuro-oncology · 2026Article
- Photodynamic therapy for recurrent spinal diffuse midline glioma with a modest extension of overall survival: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Photodynamic Therapy for Glioblastoma: Potential Application of TiOPharmaceutics · 2025Review
- Nanomedicine Approaches for Autophagy Modulation in Cancer Therapy.Small science · 2025Article
- Near-Infrared Photoimmunotherapy in Brain Tumors-An Unexplored Frontier.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Prognostic Factors and Talaporfin Sodium Concentration in Photodynamic Therapy for Recurrent Grade 4 Glioma.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Photodynamic therapy and tumor-treating fields therapy for newly diagnosed glioblastoma.Frontiers in oncology · 2025Article
- Sodium alginate hydrogel loaded with upconversion nanoparticles and magnesium ions enhances bone regeneration and photodynamic tumor therapy.Frontiers in pharmacology · 2025Article
- Combined use of 5-ALA-induced protoporphyrin IX and chlorin e6 for fluorescence diagnostics and photodynamic therapy of skin tumors.Lasers in medical science · 2024Article
- Vascular-targeted photodynamic therapy with glucose-conjugated chlorin e6 for dogs with spontaneously occurring tumours.Veterinary medicine and science · 2023Article
- Systematic Review of Photodynamic Therapy in Gliomas.Cancers · 2023Review
- Drug Delivery in Photodynamic Therapy.Pharmaceutics · 2023Article
- First Clinical Report of the Intraoperative Macro- and Micro-Photodiagnosis and Photodynamic Therapy Using Talaporfin Sodium for a Patient with Disseminated Lumbar Medulloblastoma.Journal of clinical medicine · 2023Article
- Minimally invasive treatment for glioblastoma through endoscopic surgery including tumor embolization when necessary: a technical note.Frontiers in neurology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent glioblastoma (GBM) remains one of the most challenging clinical issues, with no standard treatment and effective treatment options. To evaluate the efficacy of talaporfin sodium (TS) mediated photodynamic therapy (PDT) as a new treatment for this condition, we retrospectively analyzed 70 patients who underwent surgery with PDT (PDT group) for recurrent GBM and 38 patients who underwent surgery alone (control group). The median progression-free survival (PFS) in the PDT and control groups after second surgery was 5.7 and 2.2 months, respectively (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.